Dynamics of motor function changes in children with spinal muscular atrophy under pathogenetic therapy
- 13 November 2026
- journal article
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (3)
Abstract
Spinal muscular atrophy is a progressive and severe neuromuscular disorder and represents one of the causes of early disability and infant mortality. When SMA is suspected in a child, prompt diagnosis and timely initiation of treatment are essential, as subsequent health-related quality of life depends directly on early diagnosis and timely therapeutic intervention. Currently, several disease-modifying therapies have been developed that can influence the progression of the disease and improve the patient’s health-related quality of life. During pathogenetic treatment, changes in patients’ motor function can be observed. The most reliable way to assess this motor function dynamics is through standardized motor scales.This publication has 12 references indexed in Scilit:
- Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective studyBMC Neurology, 2023
- Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes NextAnnual Review of Genomics and Human Genetics, 2020
- Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patientsEuropean Journal of Paediatric Neurology, 2020
- Experiences from treating seven adult 5q spinal muscular atrophy patients with NusinersenTherapeutic Advances in Neurological Disorders, 2020
- AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophyGene Therapy, 2019
- De-duplicating patient records from three independent data sources reveals the incidence of rare neuromuscular disorders in GermanyOrphanet Journal of Rare Diseases, 2019
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2018
- Advances in therapy for spinal muscular atrophy: promises and challengesNature Reviews Neurology, 2018
- Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safetyPediatric Radiology, 2017
- Notable Carrier Risks for Individuals Having Two Copies of SMN1 in Spinal Muscular Atrophy Families with 2‐copy Alleles: Estimation Based on Chinese Meta‐analysis DataJournal of Genetic Counseling, 2016